(Q39460824)

12 September 2017

Strontium-89 combined with doxorubicin in the treatment of patients with androgen-independent prostate cancer (English)

1 reference

12 September 2017

1 reference

1 reference

Tu SM

1

1 reference

12 September 2017

Delpassand ES

2

1 reference

12 September 2017

Jones D

3

1 reference

12 September 2017

Amato RJ

4

1 reference

12 September 2017

Ellerhorst J

5

1 reference

12 September 2017

Logothetis CJ

6

1 reference

12 September 2017

1 November 1996

1 reference

12 September 2017

1 reference

12 September 2017

2

1 reference

12 September 2017

191-197

1 reference

12 September 2017

6

1 reference

12 September 2017

Cancer statistics, 1994.

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2897%2900013-6

7 January 2021

Results of a randomized phase-III trial to evaluate the efficacy of strontium-89 adjuvant to local field external beam irradiation in the management of endocrine resistant metastatic prostate cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2897%2900013-6

7 January 2021

Strontium-89: treatment results and kinetics in patients with painful metastatic prostate and breast cancer in bone.

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2897%2900013-6

7 January 2021

Strontium-89 chloride for pain palliation in prostatic skeletal malignancy

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2897%2900013-6

7 January 2021

Weekly doxorubicin in endocrine-refractory carcinoma of the prostate

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2897%2900013-6

7 January 2021

Experience with weekly doxorubicin (adriamycin) in hormone-refractory stage D2 prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2897%2900013-6

7 January 2021

Cellular effects of combined adriamycin and x-irradiation in human tumor cells

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2897%2900013-6

7 January 2021

Phase II study of ketoconazole combined with weekly doxorubicin in patients with androgen-independent prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2897%2900013-6

7 January 2021

Toxicity and response criteria of the Eastern Cooperative Oncology Group

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2897%2900013-6

7 January 2021

Phase II evaluation of oral estramustine and oral etoposide in hormone-refractory adenocarcinoma of the prostate

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2897%2900013-6

7 January 2021

Stratification of patients with metastatic prostate cancer based on extent of disease on initial bone scan

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2897%2900013-6

7 January 2021

Prostate-specific antigen as a measure of disease outcome in metastatic hormone-refractory prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2897%2900013-6

7 January 2021

Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points.

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2897%2900013-6

7 January 2021

10.1016/S1078-1439(97)00013-6

Identifiers

DOI

1 reference

12 September 2017

1 reference